Introduction
Cytokines such as transforming growth factor b (TGFb), interleukin 6 (IL-6), tumor necrosis factor (TNF) and interferon g (IFNg), produced by intraepithelial lymphocytes in the small intestine and by inflammatory cells present in the lamina propria, play an important role in the normal process of intestinal renewal and in a variety of immune-mediated bowel disorders. In addition, they are likely to control the progression from chronic inflammation to the development of cancer.
The JAK/STAT pathway is the principal signaling pathway utilized by several cytokines, including IFNg, a proinflammatory cytokine that has been shown to regulate intestinal renewal and to modulate epithelial barrier function (Guy-Grand et al., 1998; Bruewer et al., 2003) . Upon binding to its cell-surface receptor, IFNg triggers receptor oligomerization and activation of two receptor-associated kinases, JAK1 and JAK2, which in turn phosphorylate the latent cytoplasmic transcription factor, STAT1, on a conserved tyrosine residue (reviewed by Levy and Darnell, 2002) . Phosphorylation of STAT1 results in its dimerization and the subsequent translocation of STAT1 to the nucleus, where it binds to a specific DNA recognition sequence Shuai et al., 1992; Vinkemeier et al., 1996) . STAT1 deficiency significantly alters the biological activity of IFNg, attesting to its prominent role in signaling by IFNg. STAT1 null mice display enhanced susceptibility to viral infections (Durbin et al., 1996; Meraz et al., 1996) and have a tumor-prone phenotype (Kaplan et al., 1998; Shankaran et al., 2001) , underscoring the significance of the JAK/STAT pathway in vivo.
However, recent reports have established that IFNg can modulate the expression of several of its target genes in the absence of STAT1 (Ramana et al., 2000 (Ramana et al., , 2002 Gil et al., 2001) . For example, microarray analysis revealed that a comparable number of genes are regulated both in wild-type and STAT1-deficient bone marrow-derived macrophages , confirming that regulation of a subset of IFN target genes does not require STAT1. The nature of signaling by IFNg that bypasses the JAK/STAT pathway is not yet well understood, and signaling pathways that may play a role include candidates such as extracellular signalregulated kinase (ERK1/ERK2), phosphatidylinositol 3-kinase (PI3K), nuclear factor-kB, AKT, and potentially other members of the STAT family (Deb et al., 2001; Hu et al., 2001; Ramsauer et al., 2002; Navarro et al., 2003; Qing and Stark, 2004) .
It has become evident that chronic inflammation is an important contributing factor in tumorigenesis, and tumors have been considered to be 'wounds that never heal' (Dvorak, 1986) . For example, chronic intestinal inflammation has been shown to predispose to the development of colon cancer (Biasco et al., 2002) . In addition, the majority of precursor lesions in sporadic colorectal cancers are also frequently inflammatory in nature (Higaki et al., 1999) . Cytokines secreted by inflammatory cells can directly promote cancer cell proliferation, cell survival and angiogenesis and thereby regulate tumor progression.
One of the key links between inflammation and cellular transformation appears to be activation of cyclooxygenase-2 (COX-2), an inducible gene with a role in both inflammation and tumorigenesis. Its expression is elevated in a variety of human malignancies and their precursor lesions (Eberhart et al., 1994) , establishing COX-2 as an important target for chemopreventive agents. Indeed, anti-inflammatory agents such as non-steroidal anti-inflammatory drugs, which target the activity of COX-2, significantly reduce the risk of colorectal cancer (Brown and DuBois, 2005) .
Among known stimuli that induce COX-2 expression in intestinal epithelial cells (IECs) are activation of Ras (Sheng et al., 2001) or inactivation of the tumor suppressor gene adenomatous polyposis coli (Apc) (Araki et al., 2003) . Here, we demonstrate that IFNg is a potent inhibitor of COX-2 expression in IECs, and present data which show that IFNs modulate COX-2 transcription through a pathway that requires the activity of JAKs, but bypasses STAT1. Furthermore, global analysis of IFN-responsive genes in IECs in which STAT1 was specifically silenced by small interfering RNA (siRNA) confirmed that gene activation in response to IFNg generally requires STAT1, but that gene repression often involves pathways that circumvent STAT1 entirely, or include both STAT1-dependent and STAT1-independent signaling. Our results therefore suggest that IFNg activates and represses gene expression via distinct pathways that can be separated, at least in part, by their requirement for STAT1. Finally, we showed that Ras transformation of epithelial cells alters the balance between STAT1-dependent and STAT1-independent signaling owing to impaired expression of STAT1 in Ras-transformed cells. This is likely to have important consequences for the local inflammatory response and, therefore, the progression of intestinal tumors.
Results
IFNg inhibits COX-2 expression through a pathway that requires the activity of JAKs, but not STAT1 COX-2 expression is frequently elevated in colon cancer as a result of Apc mutations (Araki et al., 2003) or oncogenic activation of Ras (Sheng et al., 2001) . In addition, inflammatory cytokines are known to modulate the expression of COX-2 (Gupta and Dubois, 2001) . IFNg has been shown to upregulate the expression of COX-2 in murine macrophages (Vila-del Sol and Fresno, 2005) ; however, its effects on COX-2 expression in IECs have not been addressed. We therefore examined whether IFNg regulates COX-2 expression in IECs. IEC-6 cells, which express COX-2 constitutively, were stimulated with 10 ng/ml of IFNg for 24, 48 or 72 h. Treatment of IEC-6 cells with IFNg induced the expression of STAT1, a major transcription factor in IFN signaling, and interferon regulatory factor 1 (IRF-1), a downstream target of STAT1 (Figure 1a) . In contrast, IFNg in a time-dependent manner strongly inhibited the expression of COX-2. To determine whether JAKs, kinases participating in signaling by IFNg, are essential for the inhibition of COX-2 expression by IFNg, we pretreated cells with a JAK inhibitor 1 (Ji) (Calbiochem, La Jolla, CA, USA) (5 mM) for 2 h before treatment with IFNg. As shown in Figure 1b , inhibition of JAK activity completely prevented the inhibition of COX-2 expression by IFNg. Likewise, the induction of IRF-1 and STAT1 was inhibited in cells treated with Ji (data not shown). These data therefore demonstrated that the activity of JAKs is required for the inhibition of COX-2 expression by IFNg in IECs.
To determine whether STAT1, a transcription factor downstream of JAK, mediates inhibition of COX-2 by IFNs, we examined the effect of IFNg on COX-2 expression in IEC-6 cells that were transfected with STAT1 siRNA. We achieved good silencing of both basal and inducible STAT1 expression (Figure 2a) . Consistently, the induction of IRF-1, a STAT1-dependent transcription factor (Klampfer et al., 2004) , was significantly inhibited in cells with silenced STAT1 expression. In contrast, the results of several experiments revealed that IFNg retained most of its ability to inhibit the expression of COX-2 in STAT1-deficient cells (Figure 2a ). Densitometric analysis of three independent experiments, shown in Figure 2b , confirmed that IFNg downregulated the expression of COX-2, and established that the extent of COX-2 inhibition by IFNg was not affected by STAT1 deficiency. Altogether, these data strongly suggested that STAT1 is not essential for the inhibition of COX-2 expression by IFNg. As we demonstrated that the expression of IRF-1, a transcription factor that has been shown to be required for the activation of COX-2 expression by IFNg in macrophages (Blanco et al., 2000) , is inhibited in STAT1-deficient cells (Figure 2a ), these data also demonstrated that IRF-1 does not mediate the inhibition of COX-2 by IFNg in IECs. We previously reported that the expression of STAT1 is reduced in cells that harbor mutant Ras (Klampfer et al., 2003a) . Therefore, we examined whether IFNg preserves the ability to inhibit COX-2 expression upon induction of mutant Ras. To answer this question, we used IECs with isopropyl-1-thio-b-D-galactopyranoside (IPTG)-inducible expression of oncogenic RasV12, IECikRas cells (Sheng et al., 2001) . Activated Ras is induced to high levels in these cells upon addition of 5 mM IPTG (Figure 3a) , and we showed that upon induction of oncogenic Ras by IPTG, both basal and IFNg-inducible expressions of STAT1 were significantly reduced ( Figure 3b ). Consistent with published data (Sheng et al., 2001) , we showed that signaling by oncogenic Ras leads to the activation of COX-2 expression. However, despite the impaired STAT1 expression in cells with oncogenic Ras, IFNg was able to repress COX-2 expression efficiently in the presence of IPTG (Figure 3b ). In contrast, induction of IRF-1 by IFNg was inhibited by the activation of mutant Ras (data not shown), consistent with the requirement of STAT1 for the expression of IRF-1 (Figure 2a ). Altogether, these data confirmed that STAT1 is not a major transcription factor whereby IFNg inhibits the expression of COX-2.
To determine whether IFNg inhibits COX-2 expression at the level of transcription, we used IEC-ikRas cells stably transfected with a COX-2 promoter reporter (containing the 5 0 -flanking region from þ 59 to À1432) (Sheng et al., 2001) . IEC-ikRas-COX-2 5 0 cells were either left untreated or were pretreated with IPTG for 24 h and were stimulated with IFNg (1 or 5 ng/ml) or IFNb (100 U/ml) for 24 h. Induction of mutant Ras with IPTG, as described before (Sheng et al., 2001) , modestly enhanced COX-2 promoter activity ( Figure 3c ). We demonstrated that treatment of cells with IFNg or IFNb inhibits COX-2 transcriptional activity in the absence or the presence of IPTG (Figure 3c ). These data established that IFNs inhibit COX-2 expression at least in part at the level of transcription and confirmed that STAT1 does not play a major role in transcriptional inhibition of COX-2 by IFNs. In contrast, inhibition of JAK activity completely prevented the ability of IFNg to inhibit COX-2 transcriptional activity, both in the absence and in the presence of IPTG (Figure 3d ). Thus, IFNs inhibit COX-2 expression at a transcriptional level in a JAK-dependent, STAT1-independent manner.
Silencing of STAT1 expression in Hke-3 cells
Our experiments with COX-2 suggested that the pathways whereby IFNg inhibits and induces gene expression may be distinct. To determine whether there is indeed a general differential requirement for STAT1 in gene activation and gene repression in response to IFNg, we performed genome-wide analysis of IFNg-responsive genes in intestinal cells with silenced STAT1 expression. Although large-scale analysis of IFN target genes has been performed in fibroblasts and mononuclear phagocytes isolated from STAT1-deficient mice Ramana et al., 2001) , the responsiveness of epithelial cells to IFNg has not been analysed. We performed this experiment in the Hke-3 colon cancer cell line, because we showed before that these cells are, owing to genetic inactivation of the mutant Ras allele (Shirasawa et al., 1993) , highly responsive to IFNg (Klampfer et al., 2003b) . Cells were transfected with a pool of four different siRNAs directed against the coding region of the STAT1 gene (Dharmacon, Lafayette, CO, USA) or with a non-targeting, nonspecific (NSP) siRNA as we recently described (Klampfer et al., 2004) . It is important to emphasize that we transfected cells with very low concentrations (25 nM) of siRNA to avoid potential NSP effects of IFN production triggered by transfection. Twenty-four hours after transfection, cells were split into three flasks to minimize differences IFNs inhibit COX-2 expression L Klampfer et al in transfection efficiency among samples. Cells were serum starved overnight, and were then either left untreated or were treated with IFNg (10 ng/ml) for 1 or 3 h. IFNg-responsive genes that we identified by our analysis are therefore likely to represent primary target genes of IFNg. Microarray experiments were performed using the Affymetrix (Affymetrix, Santa Clara, CA, USA) U133 plus 2.0 gene chip, encompassing 47 000 sequences, as described in Materials and methods. Analysis of the microarray data confirmed that both the basal (0) (Figure 5b) . In cells in which STAT1 expression was inhibited by transfection with STAT1 siRNA, only 23 of the 236 genes remained induced twofold 3 h after treatment. Among those, 23 genes were GBP2, GBP3, IFI44, PDCD1LG and IFRG28. Therefore, silencing of STAT1 reduced the number of induced genes by 90%. However, this is a minimal estimate, as the analysis of the microarray data showed that the basal expression of the majority of these 23 genes was also significantly reduced in STAT1-deficient cells. This low basal expression following STAT1 silencing contributed to high (and probably exaggerated) calculated inducibility of these 23 genes. In reality, the expression of all these genes was severely affected by STAT1 silencing. In the group of 236 genes, we found only a few genes whose expression was truly STAT1 independent, such as solute carrier family 30 (zinc transporter), cytochrome P450 and metallothionein 1X (see Supplementary Figure 1) .
Although several other genes remained partially responsive to IFNg in the absence of STAT1, these results demonstrated that the activation of the majority of IFNg-inducible genes in IECs requires STAT1 (Figure 5a and b) . Among several other known IFNg targets, we showed that a cluster of ISGs, MyD88, phospholipid scramblase1 and Fas all require STAT1 for their induced expression by IFNg. Moreover, a subset of genes that were upregulated by IFN in cells transfected with NSP siRNA were actually downregulated by IFNg in STAT1-deficient cells, demonstrating that the absence of STAT1 resulted in perturbed response of cells to IFNs (see Figure 5a and b) .
We validated the findings from microarray analysis for four induced genes, IRF-9, b2M, KLF4 and IFIT1, by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). As shown in Figure 6a , we confirmed that the inducibility of all four genes was significantly affected by STAT1 deficiency. This experiment also demonstrated the excellent correlation between data obtained by microarray analysis and those obtained by quantitative RT-PCR (compare Figure 6a and b).
Repression of genes by IFNg occurs through both STAT1-dependent and STAT1-independent pathways
The level of gene repression in response to IFNg was expressed as the ratio of the signals between IFNgtreated cells and control, untreated cells. Therefore, only genes whose intensity of expression reached a threshold level of expression in unstimulated cells were analysed 
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further.
Here, we will present data on genes whose expression reached 50 (T ¼ 50) in untreated cells. Among those, 120 genes were repressed by IFNg twofold in Hke-3 cells 3 h after treatment with IFNg, demonstrating that the number of genes that were repressed by IFNg was lower than the number of induced genes. Twenty-five percent of genes that were reduced twofold in their expression in cells transfected with NSP siRNA were reduced to the same extent by IFN also in cells in which STAT1 had been silenced through transfection with STAT1 siRNA. In addition, the majority of the remaining genes were also reduced in expression in the absence of STAT1, although to a somewhat smaller extent, or with a delay (Figure 7a) . Thus, unlike the activation of gene expression, gene repression in response to IFNg appears to be less dependent on the presence of STAT1 and is more likely to involve STAT1-independent pathways. We found that a cluster of sequences that encode ribosomal proteins (Figure 7b ) as well as several eucaryotic translation initiation and elongation factors (Supplementary Figure 1 , not shown) were downregulated upon IFNg treatment; in most cases, the inhibition of ribosomal proteins, as in the case of COX-2 (Figure 2 ), occurred in a STAT1-independent manner (Figure 7b ). Among genes downregulated by IFN treatment were ID1, ID2 and ID3, a family of proteins that has been shown to inhibit differentiation and to stimulate proliferation (Perk et al., 2005) and SOX-9, a transcription factor important for differentiation of IECs (Blache et al., 2004) . A fourth member of the family, ID4, was poorly expressed in Hke-3 cells and its expression was not regulated by IFNg. The inhibition of ID1, ID2 and ID3 by IFNg may contribute to the prodifferentiation and antiproliferative activities of IFNg.
We confirmed by quantitative RT-PCR that inhibition of ID1, ID3 and SOX-9 by IFNg does not depend on the presence of STAT1, as it occurred both in cells transfected with NSP and STAT1 siRNA (Figure 8a ). In contrast, inhibition of ID2 expression appears to depend partially on STAT1, because it was diminished in cells with deficient STAT1 expression. These RT-PCR data again correlated well with results obtained by microarray analysis (Figure 8b) . We confirmed the quantitative RT-PCR experiment using RNA isolated from an independent experiment (data not shown) and have obtained similar results.
Discussion
IECs are in close contact with T cells from within the epithelial compartment (intraepithelial lymphocytes) as well as with lymphocytes from the underlying lymphoid tissue (lamina propria lymphocytes). These cells are a rich source of IFNg, a cytokine that, directly or through IFNs inhibit COX-2 expression L Klampfer et al stimulation of other growth factors, plays a significant role in intestinal epithelial renewal (Guy-Grand et al., 1998; Bruewer et al., 2003) . Here, we present data which demonstrate that IFNg inhibits the expression of COX-2, an important promoter of intestinal tumorigenesis and a target of pharmacological chemopreventive agents. Although IFNg activates COX-2 expression in macrophages (Blanco et al., 2000) and epidermal keratinocytes (Matsuura et al., 1999) , it has been shown to downregulate COX-2 in glioma cells (Janabi et al., 2004) , in the placenta (Hanna et al., 2004) and to inhibit TNF-induced COX-2 expression in colonic epithelial cells (Wright et al., 2004) . In this report, we established that in IECs both IFNg and IFNb inhibit basal COX-2 expression at the transcriptional level in a JAKdependent, but STAT1-independent pathway. Inhibition of COX-2 expression by IFNs is likely to contribute to the strong antiangiogenic activity of IFNs (Lindner, 2002) .
STAT1 deficiency has been shown to affect significantly the biological activity of IFNg in vitro (Ramana et al., 2000) ; however, the biological circumstances where STAT1-independent signaling may prevail remained elusive. We demonstrated that in IECs signaling by oncogenic Ras interferes with STAT1 function (Figure 3b ; Klampfer et al., 2003a) , thus identifying a physiological state in which STAT1-dependent signaling is likely to be blunted. We showed that in cells harboring mutant Ras, IFNg failed to induce the expression of genes such as IRF-1, a transcription factor required for IFNg-mediated induction of COX-2 in macrophages (Blanco et al., 2000) . In contrast, IFNg retained the ability to downregulate the expression of COX-2 in cells with activated Ras, despite the impaired expression of both STAT1 and IRF-1 in these cells. These results indicated a potential divergence in IFNg-mediated gene activation and gene repression.
To evaluate the significance of STAT1-independent signaling by IFNg in intestinal cells further, we performed genome-wide analysis of IFN-responsive genes in cells transfected with a non-targeting siRNA or STAT1-specific siRNA.
Analysis of microarray data revealed a cluster of genes that had basal expression significantly upregulated in cells with silenced STAT1 expression. Among those genes were metallothionein 1, glutathione S-transferase pi, dihydrofolate reductase, prothymosina (proteins that play a role in response of cells to stress) and MALAT-1, a novel non-coding RNA, whose expression has been shown to predict metastasis and survival in early-stage non-small-cell lung cancer (Ji et al., 2003; Muller-Tidow et al., 2004) . Because we demonstrated that cells harboring mutant Ras have reduced expression of STAT1 (Klampfer et al., 2003a) , we predicted that the ID1  ID2  ID3  SOX9  ID1  ID2  ID3  SOX9   ID1  ID2  ID3  SOX9  ID1  ID2  ID3 IFNs inhibit COX-2 expression L Klampfer et al expression of these genes should be increased in cells that harbor mutant Ras. Indeed, through analysis of genome-wide expression of isogenic cell lines that differ only by the presence of the mutant Ras, we showed that the expression of MT1 and prothymosin a is significantly increased in HCT116 cells (which contain mutant Ras), compared to two isogenic clones with targeted deletion of the mutant Ras, Hke-3 and Hkh2 cells (Klampfer et al., unpublished) . Therefore, reduced expression of STAT1 in HCT116 cells is likely to contribute to increased expression of MT1 and prothymosin a in these cells. These data also demonstrate that STAT1 is a downstream target of signaling by oncogenic Ras, which is likely to contribute to transformation of epithelial cells and to modulate their responsiveness to therapy. Our data revealed that induction of genes by IFNg, with rare exceptions, requires STAT1. In contrast, we demonstrated that IFNg retains the ability to inhibit the expression of several of its target genes in cells with silenced STAT1 expression, demonstrating that gene activation by IFNg is more sensitive to STAT1 deficiency than gene repression, and suggesting that the pathways of gene activation and gene repression by IFNg diverge downstream of JAK.
Among genes that were found to be downregulated by IFNg in a STAT1-independent manner were ID1, ID2, ID3 and SOX9, genes that play an important role in maintaining homeostasis in intestinal epithelium. This finding raises the interesting possibility that, like another antiproliferative factor, TGFb (Kowanetz et al., 2004) , IFNs inhibit proliferation and promote differentiation of epithelial cells through downregulation of the ID family members. Our ongoing experiments using ID1 and ID2 promoters indicate that IFNg inhibits ID1 and ID2 expression at the transcriptional level (Klampfer et al., unpublished) . We also found that a cluster of several ribosomal proteins and eucaryotic translation initiation and elongation factors were downregulated upon IFNg treatment in a STAT1-independent manner. Inhibition of these genes is likely to contribute to the antiproliferative and anti-viral activities of IFNs. We recently demonstrated that in vivo the expression of these genes declines as the IECs exit the proliferative compartment along the crypt villus axis (Mariadason et al., 2005) .
Although our results suggest that, generally, IFNgmediated gene activation, but not gene repression requires STAT1, we certainly found exceptions. For example, MT1, keratin-associated protein 3-1, IFNinduced transmembrane protein 1, stromal antigen 2, Hsp 70 and sialyltransferase 7 were all fully or partially induced by IFNg in cells transfected with STAT1 siRNA (see Supplementary Figure 1) . Likewise, genes such as perlecan, a heparin sulfate proteoglycan, were inhibited by IFNg in cells transfected with NSP siRNA, but failed to be inhibited by IFNg in cells transfected with STAT1 siRNA (see Supplementary Figure 1 ). This is consistent with the report that STAT1-deficient fibrosarcoma cells do not respond to IFNg with inhibition of perlecan expression (Sharma and Iozzo, 1998) . However, our data clearly demonstrate that activation of the majority of IFNg target genes requires STAT1, whereas gene repression occurs through both STAT1-dependent and STAT1-independent pathways, or bypasses STAT1 altogether. The identity of pathways whereby IFNg inhibits the expression of genes, such as COX-2, in the absence of STAT1 and the biological significance of STAT1-independent signaling remain, for now, unknown. Experiments to address these questions are underway in the laboratory. Our preliminary data have excluded the involvement of ERK and PI3K signaling in the inhibition of COX-2 expression by IFNg (not shown).
Our findings have important implications for the understanding of perturbed biological activity of IFNg in cancer cells, where STAT1 function is often impaired (Wong et al., 1997; Abril et al., 1998; Landolfo et al., 2000; Clifford et al., 2002) , such as in cells harboring Ras mutations (Klampfer et al., 2003a) . Our data predict that gene induction, but not gene repression in response to IFNg would be affected in cells that harbor mutant Ras. Indeed, we demonstrated that induction of oncogenic Ras prevented the induction of STAT1 and IRF-1 in response to IFNg, but did not interfere with the ability of IFNs to downregulate COX-2 expression. Therefore, although Ras mutations and consequent reduction of STAT1 expression do not eliminate the responsiveness of cells to IFNg, they are likely to alter the biological response to IFN significantly. Consistent with our data, it has been recently shown that the antiviral activity of IFN is abrogated in cells that carry oncogenic Ras mutation (Battcock et al., 2006) .
Materials and methods

Cells and transfections
Hke-3 cells were derived from HCT116 cells through targeted deletion of the activated Ras allele (Shirasawa et al., 1993) and, as we have reported (Klampfer et al., 2003a) , respond to IFNs with STAT1 activation. Cells were transfected with a pool of four siRNAs (Dharmacon) specific for the human STAT1 gene using the Profection Mammalian Transfection Systems (Promega, Madison, WA, USA) as we described recently (Klampfer et al., 2004) . NSP, non-targeting siRNA, was used as control. Both STAT1 and NSP siRNAs were delivered at a concentration of 25 nM. Twenty-four hours after transfection, cells were trypsinized and divided into three T25 flasks to minimize differences in transfection efficiency among samples. After reaching 80% confluency, cells were serum starved overnight and were either left untreated or were treated with 10 ng/ml of recombinant human IFNg (Biosource International, Camarillo, CA, USA) for 1 or 3 h. Rat IECs with an inducible k-RasV12 (IEC-ikRas) and IEC-ikRas cells transfected with the COX-2 promoter region (IEC-ikRas/COX-2 5 0 -LUC) were a generous gift from Raymond Dubois and were transfected with siRNA specific for rat STAT1 (Dharmacon) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
RNA isolation
RNA was isolated using TRIZOL Reagent (GIBCO BRL, Rockville, MD, USA) as suggested by the manufacturer and was further purified using the RNeasy Midi Kit (Qiagen, IFNs inhibit COX-2 expression L Klampfer et al Valencia, CA, USA). The RNA was then precipitated at À201C overnight by adding 2.5 V of ethanol and 0.1 V of 0.3 M sodium-acetate (pH 5.3). The integrity and size distribution of total RNA was monitored by denaturing agarose gel electrophoresis with detection by ethidium bromide staining.
Microarray experiments
We used human genome U133 plus 2.0 gene chips produced by Affymetrix for all experiments, which contain 47 000 gene sequences. Among the sequences on the chip, 27 160 transcripts were expressed above background ('P', as determined by Affymetrix) in at least one of the samples; only these were analysed further.
Labeled cRNA was prepared from 5 mg of RNA using The One Cycle Target Labeling Assay kit (Affymetrix) as suggested by the manufacturer. Hybridization and scanning were carried out by the Albert Einstein Cancer Center DNA facility. The results were expressed as the ratio of signals between IFNgtreated and control, untreated cells.
Quantitative RT-PCR analysis
Expression levels of selected genes that were shown to be regulated by IFNg by microarray analysis were confirmed by quantitative real-time RT-PCR analysis. RNA was isolated as described above and 1 mg of RNA was reverse transcribed using TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA). cDNA was amplified using specific primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), IRF-9, b2M and IFN/TETRA1, KLF-4, ID1, ID2, ID3 and SOX9. Primer sequences were as follows IFN/TETRA1 F: 0 ; GAPDH R-5 0 -GCCTTCCATGGTGGTGAA-3 0 . Experiments were carried out in triplicate and the expression of each gene was standardized using GAPDH as a reference. Amplification reactions were analysed using a 7900HT realtime PCR instrument (Applied Biosystems, Foster City, CA, USA). The results were expressed as the ratio between the expression of the IFNg target genes in treated and untreated cells.
